Welcome to our dedicated page for Greenwich Lifesciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich Lifesciences stock.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company dedicated to the development of groundbreaking immunotherapies aimed at preventing breast cancer recurrences. The company's flagship product, GP2, is an immunotherapy designed to stimulate the body's immune system to target and eliminate HER2/neu-expressing cancer cells, particularly in patients who have already undergone surgery for breast cancer.
GP2 leverages the HER2/neu transmembrane peptide to elicit a targeted immune response, providing a promising approach to cancer treatment. Another significant component of their pipeline is the GM-CSF Immunoadjuvant, which has shown potential in enhancing monocyte and neutrophil cytotoxicity against melanoma tumor cells, as well as boosting activity-dependent cellular cytotoxicity against targets coated with anti-ganglioside antibodies.
The company’s ongoing clinical trials are a testament to its commitment to innovation and excellence in cancer treatment. These trials are being conducted in collaboration with a steering committee comprising esteemed members from various medical institutions, ensuring rigorous oversight and adherence to the highest standards of clinical research.
Greenwich LifeSciences places a strong emphasis on advancing cancer immunotherapy to selectively stimulate an individual's immune system to attack cancer cells, thereby inhibiting the spread of the disease. Their work not only focuses on breast cancer but extends to other cancer types, showcasing a broad potential for impact in oncology.
With a robust pipeline, strategic partnerships, and a clear focus on unmet medical needs, Greenwich LifeSciences is poised to be a leader in the biopharmaceutical industry. Investors and stakeholders can stay updated on the latest developments and company performance through regular news updates and reports.
Greenwich LifeSciences (NASDAQ: GLSI) has provided an update on the open label HLA data from its Phase III FLAMINGO-01 trial, which evaluates GLSI-100 immunotherapy for breast cancer recurrence prevention. The analysis reveals that 46% of screened patients have at least one HLA-A*02 allele, meeting the expected 40-50% prevalence rate and supporting sample size estimates for the trial.
The study includes three arms: two blinded arms for HLA-A*02 patients (treatment vs. placebo) and an expanded open-label arm for non-HLA-A*02 patients, recently increased from 100 to 250 participants. Notably, 8% of patients have received HLA-A*02 alleles from both parents, which could potentially lead to greater immune response and efficacy. The trial's design allows for analysis of various HLA combinations and their prevalence across different racial and ethnic groups, which may inform future commercial development strategies.
Greenwich LifeSciences (NASDAQ: GLSI) has received EMA approval to add 11 new clinical trial sites in Spain, Germany, and Poland for its Phase III FLAMINGO-01 trial, which evaluates GLSI-100 immunotherapy for breast cancer recurrence prevention. The expansion involves academic networks including Geicam (Spain), Unicancer (France), GBG (Germany), GIM (Italy), and Polish sites, bringing the total approved European sites to approximately 110-115.
The company plans to submit applications for an additional 5-10 sites in Ireland, Romania, and potentially other European countries. Currently, GLSI has activated approximately 100 sites globally that are screening patients, with notable increased patient screening activity in the second half of 2024. The company completed site activations across five European countries in 2024, including team training for study personnel.
Greenwich LifeSciences (NASDAQ: GLSI) has announced the activation of clinical sites in Poland for its Phase III clinical trial, FLAMINGO-01, which evaluates GLSI-100 immunotherapy for breast cancer recurrence prevention. The company is collaborating with Dr. Piotr Wysocki, who leads one of Poland's largest breast cancer research networks, with 9-11 sites participating in the trial.
According to European Cancer Information System data, Poland recorded 24,599 new breast cancer cases in 2022, representing 25% of all cancers in women, with 8,723 deaths. The first patient treatment in Poland began in 2024 after site approvals by Polish authorities. Clinical sites are established across multiple cities including Konin, Kraków, Opole, Poznań, Rzeszów, Slupsk, and Warszawa.
Greenwich LifeSciences (NASDAQ: GLSI) has announced significant additions to its Phase III FLAMINGO-01 clinical trial, with Harvard University and Johns Hopkins University joining as new participating sites. The trial is evaluating GLSI-100, an immunotherapy designed to prevent breast cancer recurrences.
Dr. Laura Spring from Harvard Medical School/Massachusetts General Hospital and Dr. Cesar Santa-Maria from Johns Hopkins have joined the trial's Steering Committee, which now includes ten prominent experts representing major breast oncology networks in the US, Germany, France, and Spain. Both new committee members bring significant expertise: Dr. Spring specializes in biomarker strategies and targeted therapies, while Dr. Santa-Maria is recognized for his work in breast immunotherapy and vaccine development.
Both institutions will offer the FLAMINGO-01 trial to patients with high-risk HER2-positive breast cancer, with both physicians expressing enthusiasm about the vaccine strategy's potential to reduce recurrence risk.
Greenwich LifeSciences (NASDAQ: GLSI) provided an update on the commercial manufacturing of GP2, its immunotherapy product for preventing breast cancer recurrences. The company manufactured three commercial lots of GP2 active ingredient in 2023, sufficient for approximately 200,000 doses. In 2024, they completed the first of three commercial lots filling GP2 into vials, with final testing near completion.
The manufacturing data has been submitted to both the FDA and European regulators (EMA) for review. The company plans to complete manufacturing activities parallel to conducting the Phase III FLAMINGO-01 trial. If approved, GLSI-100 could receive up to 12 years of market exclusivity. The company is working to ensure manufacturing meets both US and European regulatory standards, with up to 150 participating clinical sites across these regions.
Greenwich LifeSciences (NASDAQ: GLSI) has announced a partnership with GBG (German Breast Group) for its Phase III clinical trial, FLAMINGO-01. The collaboration involves approximately 38 German clinical sites, with most already approved by German authorities and initiating start-up activities in 2024.
GBG, Germany's largest breast cancer research network, includes over 1,000 doctors across 800+ centers, managing 67,000+ study participants and 3,500 new patients annually. The FLAMINGO-01 trial evaluates GLSI-100, an immunotherapy designed to prevent breast cancer recurrences in HER2+ high-risk patients.
The first German patient was randomized and treated in October 2024. This partnership is significant given that Germany reported 75,267 new breast cancer cases in 2022, representing 29% of all cancers in women, with 20,601 deaths that year.
Greenwich LifeSciences (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, announced the activation of clinical sites in France for its Phase III clinical trial, FLAMINGO-01, which evaluates GLSI-100, an immunotherapy to prevent breast cancer recurrences. The trial will involve approximately 19 French sites within the Unicancer network, the largest academic breast cancer research network in France. These sites were approved by French authorities in Q1 2024, and 15 sites have already undergone initiation visits and training in 2024, with the remaining 4 sites scheduled for start-up activities in Q1-Q2 of 2025.
Unicancer, which is dedicated to oncology, brings together 18 Cancer Centers (CLCC) and cares for nearly 530,000 patients annually. Unicancer is a leading academic sponsor of clinical trials in oncology in Europe, with 106 active clinical trials in 2020 and nearly 7,600 patients enrolled. Dr. F.C. Bidard, who serves on the FLAMINGO-01 Steering Committee and is the national Principal Investigator for France, highlighted the promise of GLSI-100 in improving outcomes for patients at high risk of relapse.
CEO Snehal Patel commented on the strategic partnership with Unicancer, emphasizing the opportunity to offer FLAMINGO-01 to patients across France efficiently.
Greenwich LifeSciences (NASDAQ: GLSI) has announced a partnership with Gruppo Italiano Mammella (GIM), Italy's largest academic cooperative breast cancer research group, for its Phase III FLAMINGO-01 trial. Nine top GIM institutions, with over 150 participating centers and 500 investigators, will participate in testing GLSI-100, an immunotherapy to prevent breast cancer recurrences. The partnership addresses a significant medical need in Italy, where 58,160 new breast cancer cases were diagnosed in 2022, representing 30% of all female cancers. Patient enrollment has already begun at Italian sites, with Professor Grazia Arpino serving as the Italian National Principal Investigator.
Greenwich LifeSciences (Nasdaq: GLSI), a clinical-stage biopharmaceutical company developing GLSI-100 immunotherapy for breast cancer recurrence prevention, has provided an update on its corporate events calendar. The company has participated in multiple scientific meetings, healthcare conferences, and investment events throughout 2024, including the GBG Annual Scientific Meeting, ASCO Annual Meeting, BIO International Convention, and various healthcare investment conferences. Upcoming events include the Jefferies London Healthcare Conference, San Antonio Breast Cancer Symposium, Annual Meeting of Stockholders, and conferences extending into early 2025.
Greenwich LifeSciences (Nasdaq: GLSI) has provided an update on the expansion of its Phase III clinical trial, FLAMINGO-01, into Spain. The company has partnered with GEICAM, Spain's largest academic breast cancer research network, with 38 hospitals agreeing to participate. Approximately 30 out of 38 sites have conducted site initiation visits (SIVs), and 19 sites have been activated. Multiple sites have begun screening patients for HLA type and started treatment. The company has personally visited and trained staff at 26 out of 38 sites.
CEO Snehal Patel noted that the progress in Spain from May through July has approximately doubled the number of sites opened compared to the US. The company plans to expand the clinical trial to up to 150 sites across the US, Spain, Italy, France, Germany, and Poland.
FAQ
What is the current stock price of Greenwich Lifesciences (GLSI)?
What is the market cap of Greenwich Lifesciences (GLSI)?
What is Greenwich LifeSciences, Inc.?
What is GP2?
What does the GM-CSF Immunoadjuvant do?
What types of cancer is Greenwich LifeSciences targeting?
Who oversees the clinical trials at Greenwich LifeSciences?
What is the significance of HER2/neu in cancer treatment?
Are there any ongoing clinical trials?
How can investors stay updated on the company?
What makes Greenwich LifeSciences' approach unique?
Where can I find more information about Greenwich LifeSciences?
